PROGETTO: “ A phase 3, multicentre, open-label, randomized controlled study to compare the efficacy and safety of Sotrovimab (Xevudy®) or Tixagevimab and Cilgavimab (Evusheld®) or Nirmatrelvir co-packaged with Ritonavir (Paxlovid®) in preventing clinical worsening in COVID-19 home patients at high risk of hospitalization” ( titolo breve: MAI COVID19 ) , da svolgersi presso il Dipartimento di Cure Primarie